Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

Complete title: NANT 2014-01 Phase I Study of SF1126 for Patients with Relapsed or Refractory Neuroblastoma

Research Study Number NANT 2014-01
Principal Investigator Julie Park, MD
Phase I

Research Study Description

SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 3+3 dose escalation design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 10 patients with tumors with MYCN amplification, Mycn expression, or Myc expression will be treated.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number NANT 2014-01
Contact Advanced Therapeutics Study Line
Telephone 206/987-2553

Keywords: Neuroblastoma; Neuroectodermal Tumors, Primitive (PNET); Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials